MINocyclinE to Reduce inflammation and blood brain barrier leakage in small Vessel diseAse (MINERVA) trial study protocol.

ABSTRACT:

Background

Cerebral small vessel disease (SVD) is a common cause of stroke and cognitive impairment. Recent data has implicated neuroinflammation and increased blood-brain barrier (BBB) permeability in its pathogenesis, but whether such processes are causal and can be therapeutically modified is uncertain. In a rodent model of SVD, minocycline was associated with reduced white matter lesions, inflammation and BBB permeability.

Aims

To determine whether blood-brain barrier permeability (measured using dynamic contrast-enhanced MRI) and microglial activation (measured by positron emission tomography using the radioligand ¹¹C-PK11195) can be modified in SVD.

Design

Phase II randomised double blind, placebo-controlled trial of minocycline 100 mg twice daily for

SUBMITTER: Brown RB 

PROVIDER: S-EPMC9445404 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature